By Fineline Cube 
US pharmaceutical heavyweight Pfizer Inc. (NYSE: PFE) posted Q3 2025 revenues of $16.7 B – a 7 % year‑on‑year decline. The fall is largely attributed to a sharp contraction in COVID‑19 product sales, as lower infection rates curb demand for Paxlovid and a tighter U.S. vaccine recommendation shrinks the Comirnaty‑eligible cohort.
Key Performance Highlights
| Product | Y/Y Change | 3‑Month Revenue (USD B) |
|---|---|---|
| Eliquis (apixaban) / BMS | +22 % | 2.01 B |
| Vyndaqel (tafamidis) | +7 % | 1.59 B |
| Nurtec ODT / Vydura (rimegepant) | +22 % | 0.412 B |
| Padcev (enfortumab vedotin) | +7 % | 0.464 B |
| Paxlovid (nirmatrelvir/ritonavir) | ‑55 % | 1.23 B |
| Comirnaty (BNT162b2) | ‑20 % | 1.15 B |
- Launch & Acquired Products: $7.3 B of revenue, 8 % YoY growth.
- Full‑Year Guidance: Revenue unchanged at $61–64 B; adjusted diluted EPS raised to $3.00–$3.15 from $2.90–$3.10.
What Drives the Numbers?
COVID‑19 Revenue Drag
- Paxlovid sales plunged 55 % to $1.23 B as the U.S. pandemic curve flattens.
- Comirnaty revenue fell 20 % to $1.15 B, reflecting a narrowed vaccination campaign in the U.S.
Portfolio Resilience
Eliquis and other non‑COVID indications offset the loss. The company stresses its 2025 outlook remains robust, with adjusted EPS guidance climbing to the $3.00–$3.15 band, signaling confidence in its pipeline and global sales momentum.
Outlook
Pfizer’s unchanged revenue guidance of $61–64 B for FY25 reflects a balanced portfolio: a 7‑% revenue decline in COVID products is balanced by double‑digit gains from Eliquis, Nurtec, Padcev, and a modest lift from new launches. The company’s upgraded EPS guidance indicates stronger profitability expectations amid a shifting therapeutic landscape.-Fineline Info & Tech